Ieq Capital LLC Has $11.88 Million Stake in Gilead Sciences, Inc. $GILD

Key Points

• Ieq Capital LLC significantly increased its stake in Gilead Sciences by 59.0%, owning nearly 106,000 shares worth approximately $11.88 million.
• Gilead Sciences achieved a quarterly earnings report with $2.01 earnings per share, exceeding analyst expectations and showing a 1.4% year-over-year revenue growth.
• The company declared a quarterly dividend of $0.79 per share, resulting in a 2.8% dividend yield, with payment scheduled for September 29th.

Ieq Capital LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 59.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 105,990 shares of the biopharmaceutical company's stock after purchasing an additional 39,330 shares during the quarter. Ieq Capital LLC's holdings in Gilead Sciences were worth $11,876,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of GILD. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $25,000. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $29,000. Colonial Trust Advisors increased its position in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 213 shares during the last quarter. Core Alternative Capital increased its position in shares of Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 241 shares during the last quarter. Finally, IMA Advisory Services Inc. acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $39,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Royal Bank Of Canada lifted their price target on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a report on Friday, August 8th. UBS Group lifted their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Finally, Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Trading Down 0.7%

Shares of NASDAQ:GILD opened at $113.92 on Thursday. Gilead Sciences, Inc. has a 12-month low of $77.23 and a 12-month high of $121.83. The stock has a market cap of $141.35 billion, a PE ratio of 22.69, a P/E/G ratio of 0.70 and a beta of 0.33. The business has a 50 day moving average of $112.83 and a 200-day moving average of $109.35. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business's revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is 62.95%.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the sale, the director owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 82,000 shares of company stock valued at $9,339,230. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.